Prognostic Significance of the CXCL11/CXCL9/CD163 Immune Signature in Triple-Negative Breast Cancer: A Bioinformatics and Survival Analysis
Archives of Breast Cancer · 22.04.2026 · 13 (2) · 154-165
DOI: 10.32768/abc.6274819305-647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Breast Cancer, online erschienen am 22.04.2026. Verfasst von Isra Alhamadani und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature and poor prognosis. Although characterized by a significant immune infiltration, this characteristic often fails to provide protection, requiring precise identification of the genetic hubs driving this failure. This study aimed to identify an immune gene signature associated with favorable prognosis in TNBC using a bioinformatics approach.
Methods
Gene expression data were extracted from the GSE53752 dataset (Gene Expression Omnibus [GEO], platform GPL13607), including 51 TNBC tumor and 25 normal tissue sample. Differential expression analysis was performed, followed by functional enrichment and protein–protein interaction network (STRING) analysis to identify key immune pathways. Relapse-free survival (RFS) was evaluated for individual genes and for the combined CXCL9/CXCL11/CD163) signature using the Kaplan-Meier Plotter (n = 533).
Results
Enrichment analysis demonstrated the dominance of chemokine signaling pathways and the inflammatory response. STRING analysis revealed a robust network centered on chemokines CXCL9, CXCL11, and the macrophage marker CD163. Multivariate Cox regression analysis confirmed that the CXCL9/CXCL11/CD163 signature is an independent predictor significantly associated with a reduced RFS rate (HR = 0.45; P = 2.3 × 10−6, indicating a twofold increase in risk in patients with high signature activation. Notably, traditional clinical factors did not reach statistical significance.
Conclusion
The CXCL11/CXCL9/CD163 axis represents a strong, independent positive prognostic factor in TNBC. These findings contribute to our understanding of the immune failure mechanisms and confirm that the CXCL11/CXCR3 signal intensity is a key determinant of prognosis, making this axis a promising therapeutic target for modulating the tumor microenvironment.
Zitieren
APA
Alhamadani, I., Alzyadi, M., & Majeed, M. (2026). Prognostic Significance of the CXCL11/CXCL9/CD163 Immune Signature in Triple-Negative Breast Cancer: A Bioinformatics and Survival Analysis. Archives of Breast Cancer, 13(2), 154-165. https://doi.org/10.32768/abc.6274819305-647
Vancouver
Alhamadani I, Alzyadi M, Majeed M. Prognostic Significance of the CXCL11/CXCL9/CD163 Immune Signature in Triple-Negative Breast Cancer: A Bioinformatics and Survival Analysis. Archives of Breast Cancer. 2026;13(2):154-165. doi:10.32768/abc.6274819305-647
BibTeX
@article{Alhamadani2026,
author = {Alhamadani, Isra and Alzyadi, Mohammed and Majeed, Mohauman},
title = {Prognostic Significance of the CXCL11/CXCL9/CD163 Immune Signature in Triple-Negative Breast Cancer: A Bioinformatics and Survival Analysis},
journal = {Archives of Breast Cancer},
year = {2026},
volume = {13},
number = {2},
pages = {154--165},
doi = {10.32768/abc.6274819305-647}
}
EUVIMED